Neurocrine Biosciences Highlights INGREZZA® Success in Tardive Dyskinesia Treatment Findings

Neurocrine Biosciences Advances Tardive Dyskinesia Treatment with INGREZZA® Findings

Neurocrine Biosciences, Inc. has recently unveiled compelling results from a post-hoc analysis of its Phase 4 KINECT-PRO™ study, focusing on the effectiveness of INGREZZA® (valbenazine) in treating tardive dyskinesia (TD). Presented at Psych Congress 2025, the analysis reports that 57.8% of TD patients achieved symptomatic remission by Week 24 of treatment. The results are stratified by dosage, with remission rates of 58.3% for those on 40 mg, 44.4% for 60 mg, and 62.5% for 80 mg. This data not only underscores the drug's efficacy but also highlights a critical advancement in treatment methodologies for a condition that significantly impacts patients' quality of life.

The KINECT-PRO analysis demonstrates that symptomatic remission can be achieved sooner than previously understood, a finding that Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, emphasizes as pivotal in the management of TD. The study included a diverse patient population with varying severity levels of TD, reflecting real-world complexities and the ability of INGREZZA to address a broad spectrum of symptoms. Significant improvements were also noted in patient-reported outcomes, including metrics from the Tardive Dyskinesia Impact Scale (TDIS™) and the EuroQoL Visual Analog Scale (EQ-VAS), indicating that patients not only experience a reduction in involuntary movements but also enhancements in their physical, social, and emotional well-being.

The implications of these findings extend beyond mere statistics; they signal a potential shift in the treatment landscape for TD. As Neurocrine continues to innovate, the positive outcomes associated with INGREZZA could reshape patient expectations and treatment goals. This is particularly relevant in an industry that is increasingly focused on patient-centric approaches. With ongoing research, Neurocrine Biosciences is positioned to address the pressing needs of those suffering from neurological disorders, reinforcing its commitment to advancing therapies that improve patient lives.

In a broader context, the recent evaluations from analysts regarding Neurocrine’s market performance reflect a complex landscape marked by innovation and uncertainty. These assessments are particularly relevant as the company navigates regulatory challenges and competitive pressures within the biopharmaceutical sector. The insights from industry analysts will continue to be crucial for stakeholders assessing Neurocrine's long-term viability and potential growth, especially as the healthcare market evolves rapidly.

As Neurocrine Biosciences moves forward, the successful outcomes from the KINECT-PRO study serve as both a validation of its research efforts and a beacon of hope for patients battling tardive dyskinesia. With ongoing advancements, the company is set to play a significant role in shaping the future of treatment options in this challenging therapeutic area.